The Happy Lungs Project is pleased to share research that we are funding in collaboration with our sister organizations, RETpositive and Lungevity.
Original article: https://www.lungevity.org/news/media-releases/retpositive-and-lungevity-foundation-partner-on-innovative-lung-cancer-research
RET-positive lung cancer community funds research into critical areas of need
Patient group RETpositive and LUNGevity Foundation today announced the 2022 recipients of the first RETpositive/LUNGevity Translational Research Award for RET-Positive Lung Cancer. RET is a driver mutation found in approximately 1%-2% of people with non-small cell lung cancer. The goal of these awards is to transform the future for those diagnosed with RET-positive lung cancer by changing RET-positive lung cancer into a chronic or curable condition. These awards total $100,000 each for a two-year term. Funds were raised by RETpositive, a patient-driven nonprofit that aims to improve the quality of life and life expectancy of RET-positive cancer patients.